Drug discovery seeds partners

Japanese firms Ube and Fronteo have entered into a basic agreement for joint research aimed at generating and out-licensing drug discovery seeds to pharmaceutical companies. They plan to determine the target disease area by December and begin research in January.

The partnership will use Fronteo’s AI drug discovery support service, Drug Discovery AI Factory (DDAIF) to explore previously unreported relationships between diseases and target molecules, along with Ube’s expertise and technological capabilities to generate and optimise compounds that act on target molecule candidates discovered through DDAIF.